bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-71-3425

Order Name:
Tempus xT panel & PD-L1 & HRD, tissue (FFPE) + Blood **

 
Useful For:
To help dentify treatment options tailored for the individual cancer patient.
Tempus targeted gene panel focused on actionable mutations by DNA sequencing, and Full transcriptome by RNA sequencing. Plus PD-L1 testing. Plus HRD testing.
 
Methodology:
DNA sequencing using tumor/normal match
RNA sequencing (Whole transcriptome RNA sequencing with validated fusion detection)
IHC for PD-L1 (upto 2 clones, selection from 22C3, 28-8, or SP142)
DNA-based test for HRD
 
Test List In Profile:
xT-648 gene panel
RNA expression
PD-L1 
HRD
 
AliasesName:
xT Solid Tumor + PD-L1 + HRD
 
 
 
Test Code:
090-71-3425

Order Name:
Tempus xT panel & PD-L1 & HRD, tissue (FFPE) + Blood **

 
Collection Specimen Or Container:
FFPE tissue block (at least 20% tumor) + H&E slide(optional)
+ Blood (Tempus Kit) - Two 10mL Streck tubes, sending ASAP

Document Required
- Filled Requisition Form & Sign Consent 
- Pathology report
- Progress note
 
Specimen Testing Type:
10 FFPE unstained slides for NGS, 5 um sections on positivelt charged, un baked slides**
1   Terminal H&E stained slide
3   FFPE unstained slides for PD-L1 IHC
+ Whole blood 10mL Streck x 2 tubes 

**Submit 10 additional slides if tissue is <25 mm2
 
Sub Mission Container:
Tempus tissue collection Kit  +  Tempus blood collection Kit
 
 
Specimen Stabillity:
Specimen Type Temperature Time
Whole blood Ambient temperature 7 days *
* Sent to USA
 
 
 
Test Code:
090-71-3425

Order Name:
Tempus xT panel & PD-L1 & HRD, tissue (FFPE) + Blood **

 
Method detail:
DNA sequencing using tumor/normal match
RNA sequencing (Whole transcriptome RNA sequencing with validated fusion detection)
IHC for PD-L1 (upto 2 clones, selection from 22C3, 28-8, or SP142)
DNA-based test for HRD
 
 
Schedule:
N/A **Sent out to Ontarget Medicine Co, Ltd. (Tempus, USA).
 
 
Turnaround Time:
Received specimen to reported within 4-5 weeks (Slide received to report)
 
Performing Location:
Ontarget Medicine Co, Ltd. (Tempus, USA).
Referral Lab Services, Laboratory Department 14160-2
 
 
 
Test Code:
090-71-3425

Order Name:
Tempus xT panel & PD-L1 & HRD, tissue (FFPE) + Blood **

 
 
Clinical Information:
These tests can predict which patients are at higher risk, and therefore might benefit from adjuvant therapy, as well as other endpoints that can positively impact a patient’s journey.

HRD TEST
The Tempus Homologous Recombination Deficiency (HRD) test is a DNA-based test, available as part of the xT platform, for clinicians aiming to better understand if their patient has Homologous Recombination Deficiency. Tempus HRD is a comprehensive view into a patient’s ability to repair double-stranded DNA breaks. HRD status can be used to identify patients who may be sensitive to PARP inhibitors and/or platinum-based chemotherapy.

The Tempus HRD test takes into account results from our xT Sequencing Panel, giving a full view into 18 commonly mutated genes in the HR-pathway, along with a genome wide loss-of-heterozygosity (LOH) score, giving a clinician one of the most complete views of HRD status on the market. The HRD test can be ordered with 6 major cancer subtypes: Ovarian, Breast, Pancreatic, Prostate, Non-small-cell lung cancer, and Glioblastoma, and does not require additional tissue from the patient.
 
Interpretation:
Tempus reports associate potentially relevant therapies with detected genomic alterations and prioritize them based on the strength of the clinical evidence.
 
Clinical Reference:
www.tempus.com (Retrieved: 5 Mar 2021)